![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, December 26, 2021 11:31:27 PM
dehaze
search
close
SIGN IN
?
U.S. Severe Oral Mucositis Market to Surpass US$ 267.7 Million by 2028, Says Coherent Market Insights (CMI)
August 12, 2021 09:20 ET| Source: CMI
SEATTLE, Aug. 12, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S. Severe Oral Mucositis Market is estimated to be valued at US$ 78.5 million in 2021 and is expected to exhibit a CAGR of 19.2% during the forecast period (2021-2028).
Key Trends and Analysis of the U.S. Severe Oral Mucositis Market:
Key players operating in the market are focusing on the development of treatments for severe oral mucositis, which is expected to offer lucrative opportunities for the market players to launch novel products in the market. For instance, in June 2020, Soligenix, Inc. announced that it completed patient enrolment in its Phase 3 DOM-INNATE study for SGX942 (dusquetide) in the treatment of oral mucositis (OM) in head and neck cancer (HNC) patients.
For instance, in February 2020, Galera Therapeutics, Inc. announced full tumor results of the two year follow up of patients with head and neck cancer treated with avasopasem manganese (GC4419), which is Galera’s lead product candidate for severe oral mucositis (SOM) and is curently in a Phase 2b clinical trial.
Key Market Takeaways:
The U.S. severe oral mucositis market is expected to exhibit a CAGR of 19.2% during the forecast period due to increasing prevalence of head and neck cancer in the U.S., which is expected to boost the U.S. severe oral mucositis market in 2028. For instance, according to the Centers for Disease Control and Prevention report, around 650,000 cancer patients receive chemotherapy in an outpatient setting each year in the U.S. and according to a consensus about 500,000 cases of OM occur in the U.S. every year.
Recent GRTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 11:02:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 11:00:54 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 02:26:45 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 05/16/2024 02:26:17 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/16/2024 02:25:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 11:30:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:05:31 AM
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 05/13/2024 11:00:00 AM
- Galera Adopts Limited Duration Stockholder Rights Agreement • GlobeNewswire Inc. • 05/03/2024 11:00:00 AM
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:06:04 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/20/2024 11:57:58 PM
- Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 11/14/2023 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/13/2023 07:24:56 PM
- Galera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 Trial • Dow Jones News • 10/31/2023 12:09:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 11:10:53 AM
- Galera Announces Receipt of Type A Meeting Minutes and Strategic Update • GlobeNewswire Inc. • 10/31/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 11:24:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 09:12:53 PM
- Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:30:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 11:10:28 AM
- Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 08/14/2023 11:00:17 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM